These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

433 related items for PubMed ID: 18647300

  • 1. Perceived control over ejaculation is central to treatment benefit in men with premature ejaculation: results from phase III trials with dapoxetine.
    Shabsigh R, Patrick DL, Rowland DL, Bull SA, Tesfaye F, Rothman M.
    BJU Int; 2008 Sep; 102(7):824-8. PubMed ID: 18647300
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Validity of the patient-reported Clinical Global Impression of Change as a measure of treatment response in men with premature ejaculation.
    Althof SE, Brock GB, Rosen RC, Rowland DL, Aquilina JW, Rothman M, Tesfaye F, Bull S.
    J Sex Med; 2010 Jun; 7(6):2243-2252. PubMed ID: 20367770
    [Abstract] [Full Text] [Related]

  • 4. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine.
    McMahon C, Kim SW, Park NC, Chang CP, Rivas D, Tesfaye F, Rothman M, Aquilina J, Dapoxetine 3003 Study Investigators.
    J Sex Med; 2010 Jan; 7(1 Pt 1):256-68. PubMed ID: 19878447
    [Abstract] [Full Text] [Related]

  • 5. Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries.
    Buvat J, Tesfaye F, Rothman M, Rivas DA, Giuliano F.
    Eur Urol; 2009 Apr; 55(4):957-67. PubMed ID: 19195772
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study.
    McMahon CG, Giuliano F, Dean J, Hellstrom WJ, Bull S, Tesfaye F, Sharma O, Rivas DA, Aquilina JW.
    J Sex Med; 2013 Sep; 10(9):2312-25. PubMed ID: 23845016
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials.
    McMahon CG, Althof SE, Kaufman JM, Buvat J, Levine SB, Aquilina JW, Tesfaye F, Rothman M, Rivas DA, Porst H.
    J Sex Med; 2011 Feb; 8(2):524-39. PubMed ID: 21059176
    [Abstract] [Full Text] [Related]

  • 8. Dapoxetine: in premature ejaculation.
    Hoy SM, Scott LJ.
    Drugs; 2010 Jul 30; 70(11):1433-43. PubMed ID: 20614950
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A benefit-risk assessment of dapoxetine in the treatment of premature ejaculation.
    Hutchinson K, Cruickshank K, Wylie K.
    Drug Saf; 2012 May 01; 35(5):359-72. PubMed ID: 22452563
    [Abstract] [Full Text] [Related]

  • 17. Premature ejaculation and pharmaceutical company-based medicine: the dapoxetine case.
    Waldinger MD, Schweitzer DH.
    J Sex Med; 2008 Apr 01; 5(4):966-997. PubMed ID: 18371047
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Oral agents for the treatment of premature ejaculation: review of efficacy and safety in the context of the recent International Society for Sexual Medicine criteria for lifelong premature ejaculation.
    McMahon CG, Porst H.
    J Sex Med; 2011 Oct 01; 8(10):2707-25. PubMed ID: 21771283
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.